StreetAlpha.app
Home › Stocks › HROW

Harrow, Inc. (HROW)

Healthcare
$29.52
▲ +1.48%
LAST CLOSE · NOV 17

Harrow sells eye care medicines and compounded eye formulations to eyecare doctors and their patients. It last closed at $29.52 on Nov 17, up 1.48% on the day. HROW last reported earnings on Mon, Nov 9, 2026.

AI Auto Pilots
Is HROW in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$303.3M
+21.3% vs a year ago
Net income
−$28.5M
−9.4% margin
EPS (diluted)
−$0.76
Free cash flow
−$20.4M
−6.7% margin
Valuation
Market cap
$1.1B
37.5M shares
P/E
–
No P/E while losing money
Price to sales
3.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$75.3M
At Sep 30
Debt
$292.7M
At Sep 30
Shareholder equity
$29.2M
Shares outstanding
37.5M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $72.5M$72.5MFY2021FY2022: $88.6M$88.6MFY2022FY2023: $130.2M$130.2MFY2023FY2024: $199.6M$199.6MFY2024FY2025: $272.3M$272.3MFY2025

From HROW's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · After the close (AMC)
Reported EPS
$0.12
vs $0.13 est. · miss
Year-ago EPS
—
Not on file
Options-implied move
±12.1%
Priced in before that report
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated HROW in the past 90 days, not enough for a consensus
Average 12-month target
$45.00
▲ 52.4% upside

Based on 1 analyst who set a price target on HROW in the past 90 days. The average target is $45.00, with a high of $45.00 and a low of $45.00, compared with the last close of $29.52.

Low $45.00Avg $45.00High $45.00
Blue marker: last close $29.52
Highest target$45.00
Average target$45.00
Lowest target$45.00
Latest rating changes
Leerink PartnersInitiated
Sep 9Buy$45
BTIGReiterated
Jul 21Buy$63
DateFirmActionRatingPrice target
Sep 9Leerink PartnersInitiatedBuy$45
Jul 21BTIGReiteratedBuy$63
Loading…

Technical Analysis

HROW · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is 27% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 51). The nearest support is the Pivot at $29.32, and the nearest resistance the Pivot R1 at $29.88.

Short trendNeutral
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 5.9%/day
Key levels
$54.8552 week high+85.8%
$37.37200 day average+26.6%
$35.59100 day average+20.6%
$30.4250 day average+3.0%
$30.28Swing high (Oct 29)+2.6%
$29.88Pivot R1+1.2%
$29.52Last close
$29.32Pivot−0.7%
$28.95Pivot S1−1.9%
$28.6620 day average−2.9%
$27.14Swing low (Oct 23)−8.1%
$25.7652 week low−12.7%
Indicators
RSI (14)51.03Middle of its rangeNeutral
MACD-0.31Above its signal lineBullish
Stochastic48.2Middle of its rangeNeutral
ADX (14)33.3Trending up
Williams %R-52.5Oversold below −80, overbought above −20Neutral
CCI (20)49.6Oversold below −100, overbought above 100Neutral
Rate of change+3.4%Change over 10 sessionsBullish
ATR (14)$1.74Typical daily range, 5.9% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for HROW

What happened before

See how HROW did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow HROW usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How HROW has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in HROW in the last 90 days.

Loading…

See today’s whale options flow across the market →

HROW Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼93 buying vs 110 selling
  • ▲Held by funds +2.8 pts
  • ▼Funds holding -16
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding208224−7.1%
In funds' top 1034−25.0%
Held by funds60.2%57.3%+2.8 pts
New / increased25 / 6838 / 81−21.8%
Reduced / sold out68 / 4264 / 35+11.1%
Put/call ratio0.251.81−86.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See HROW institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HROW is in one of them and how their past HROW trades turned out.

HROW in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered HROW in an article yet. Here's the latest on the wider market.

About Harrow

Harrow sells eye care medicines, mainly in the United States and Canada. Its branded portfolio includes eye drops and injections for conditions such as dry eye disease, pain after cataract surgery, bacterial eye infections, allergic itching and wet macular degeneration. The company also runs a compounding pharmacy business that supplies custom formulations. Its customers are eyecare doctors, surgeons and their patients. Harrow is based in Nashville, Tennessee.

Headquarters
Nashville, TN
Founded
1998